Parasitic infections of the lung: a guide for the respiratory physician

H Kunst, D Mack, O M Kon, A K Banerjee, P Chiodini, A Grant

ABSTRACT
Parasitic infections of the lung occur worldwide among both immunocompetent and immunocompromised patients and may affect the respiratory system in a variety of ways. This review provides an update on the presenting symptoms, signs, investigation and management of diseases affecting the lung caused by protozoa, nematodes and trematodes. The clinical presentations and radiographic findings of several of these diseases may mimic tuberculosis and malignancy. It is important to consider parasitic infections in the differential diagnosis of such lung diseases. If identified early, most parasitic diseases that affect the lung are curable with medical or surgical treatments.

INTRODUCTION
With increasing travel and migration, rates of parasitic lung and pleural diseases are increasing in the immunocompetent population in developed countries as well as among immunocompromised patients. Respiratory physicians should consider parasitic diseases in the differential diagnosis of lung conditions such as tuberculosis and malignancy, with which parasitic lung diseases may be confused.

This review describes the presentation, investigation and management of common parasitic infections affecting the lung caused by protozoa, nematodes and trematodes. The diseases have been grouped according to their manner of presentation: (1) those presenting with focal lesions and (2) those which characteristically present with diffuse lung disease. Focal lung lesions have been divided into cystic lung lesions, coin lesions and consolidation/pleural effusion. Diffuse lung disease has been divided into transient pulmonary infiltrates and alveolar/interstitial lung changes. Diseases that may present in a variety of ways are fully described only the first time they are mentioned.

CONDITIONS PRESENTING WITH FOCAL LUNG LESIONS
Cystic lung lesions
Hydatidosis
Distribution and life cycle
Hydatid disease is caused by larvae of Echinococcus tapeworm species, the definite hosts of which are members of the Canidae family (dogs and foxes). Most cases are caused by Echinococcus granulosus which has a worldwide distribution including South America, countries surrounding the Mediterranean, the Middle East, some sub-Saharan African countries, Russia and China. Although most cysts form in the liver, 20–30% form in the lung.

Dogs are the definitive host for E granulosus and harbour the adult worms in their gut. The eggs shed in dog faeces remain viable for many weeks and are able to contaminate food sources of intermediate hosts such as sheep, cattle and horses. When humans become accidental intermediate hosts after eating food contaminated with eggs, the ingested eggs hatch, releasing larvae which migrate from the gastrointestinal tract to the circulation. The eggs travel to the liver or lungs and slowly develop into hydatid cysts over a period of several months or years. Occasionally, lung cysts form after transdiaphragmatic spread of parasites following the rupture of liver cysts.

Presentation
Primary infection is asymptomatic and patients may remain asymptomatic for years, during which time lung lesions may be discovered incidentally on a chest x-ray. In Europe the average patient is in their 50s at diagnosis.

Cysts may cause symptoms by compression of adjacent structures, and lung cysts may present with chest pain, cough, haemoptysis or pneumothorax. Symptoms may also occur if antigenic material is released from the cyst, causing a hypersensitivity reaction with fever, wheeze and urticaria and, rarely, anaphylaxis. Cysts may become secondarily infected causing empyema or lung abscess formation.

Imaging features
Cysts can be seen as single or multiple well-defined homogenous lesions surrounded by otherwise normal lung parenchyma on a plain chest x-ray. The lower lobes, posterior lung segments and the right lung are affected most frequently.

The cyst wall often calcifies over time. A CT scan of the chest may reveal further diagnostic features including collapse of the laminated membrane from the surrounding host tissue, the presence of daughter cysts and the presence of cyst rupture.

Air between the host tissue and laminated membrane of ruptured cysts may produce crescent-shaped lucencies. A pleural effusion or a hydropneumothorax may develop following the rupture of a pulmonary cyst into the pleural space. Collapsed laminated membrane may float in the cyst cavity, producing the ‘water lily’ sign (figures 1 and 2).

Laboratory diagnosis
Peripheral blood eosinophilia may be found in no more than 50% of cases. A substantial rise in eosinophil count is often associated with a leakage of antigenic material from the cyst. Serological tests to support the initial diagnosis are available at reference laboratories but are less sensitive for the diagnosis of lung disease than for hepatic disease.
Postoperatively, serological tests may be used to monitor the immunological response to treatment.  
While percutaneous aspiration of liver cysts under ultrasound guidance can support the diagnosis by demonstrating the presence of protoscolices or hooklets, this is not generally recommended because of the risk of leakage resulting in an anaphylactic reaction.

Management
In a small number of cases hydatid cysts resolve spontaneously. In the majority of cases the treatment of choice is surgical excision of cysts with a view to preserve as much lung parenchyma as possible. Albendazole should be avoided preoperatively as it may soften the cyst wall and increase the chance of rupture. It may be given as adjunctive therapy once the cyst has been removed. When surgery is contraindicated or not feasible in patients with multiorgan involvement, medical treatment with albendazole with or without praziquantel is recommended. Expert advice should be sought regarding chemotherapeutic regimens before and after surgery and for cases where surgery is not to be carried out. While aspiration followed by injection of a scolicidal agent and re-aspiration (PAIR) has been used as a therapeutic tool when surgery is contraindicated, the World Health Organization states that PAIR is contraindicated for lung cysts and the authors endorse that view.  

Coin lesions
Dirofilariasis
Distribution and life cycle
Pulmonary dirofilariasis is caused by the dog heartworm Dirofilaria immitis and has been reported from Japan, Australia, the USA and Italy (D repens). Adult worms live in the right ventricle of the definitive canine hosts and produce circulating microfilaria which can be transmitted by a variety of mosquito species to humans. In humans the worms pass through the right ventricle but fail to mature and are swept away to peripheral pulmonary arteries.

Presentation
Most patients are asymptomatic, although symptoms including chest pain, cough, haemoptysis, wheezing, fever, chills and malaise have been reported.

Imaging features
The most common presentation is with a coin lesion on chest radiography. These are usually 1–3 cm in diameter and sharply defined. In established lesions a central necrotic area is surrounded by a granulomatous reaction and fibrous wall. Dead worms may calcify. Positron emission tomographic scanning may show an increased uptake of fluorodeoxyglucose around necrotic nodules, a feature also seen in other infectious lung nodules.

Laboratory diagnosis
Eosinophilia may be present in a small number of patients. There are no reliable serological tests available commercially. Most cases are diagnosed by identifying the worm in biopsy specimens after thoracotomy for a pulmonary nodule thought to be a malignancy.

Management
Chemotherapy is ineffective. The only treatment is surgical excision if indicated.

Consolidation/pleural effusion
Paragonimiasis
Distribution and life cycle
Pulmonary paragonimiasis is most frequently seen in south east Asia but also occurs in central Africa and South America. It is caused by lung flukes of the genus Paragonimus. Paragonimus westermani is responsible for most cases. The adult worms are found in pulmonary cysts, usually in pairs. Adult worms produce eggs which are secreted in sputum or faeces. Humans are usually infected by eating the second intermediate host, fresh water crab or crayfish, if raw or lightly cooked. After ingestion the larvae penetrate the intestinal wall and migrate to the lung parenchyma. They mature in a fibrous host-derived capsule, usually in the upper zones of the lung.

Presentation
Presenting symptoms include pleuritic chest pain, haemoptysis, chronic cough and fever. If pulmonary cysts erode into adjacent bronchi, patients may suffer life-threatening haemoptysis.

Imaging features
Radiographic features of paragonimiasis include patchy air space consolidation, cystic changes and ring shadows. Pleural effusions and pneumothoraces may occur. On the CT scan round low-attenuation cystic lesions filled with fluid or gas may be seen within an area of consolidation. Peripheral linear opacities seen on chest x-rays are suggestive of worm migration tracks on corresponding CT scans. Intracystic worms may be detected on a CT scan of the thorax. Patients with pulmonary

Figure 1 Chest x-ray showing a hydatid cyst in the left lower lobe with a collapsed hydatid cyst exhibiting the ‘lily pad’ sign lying above it.

Figure 2 CT scan of the thorax showing a ruptured hydatid cyst in the left upper lobe of the lung.


Review
paragonimiasis who present with parenchymal lesions on a CT scan of the thorax may have bronchial stenosis on bronchoscopy. Paragonimiasis is often misdiagnosed as tuberculosis or malignant disease and should be considered in the differential diagnosis of these conditions in those who have lived in endemic countries.

**Laboratory diagnosis**

Peripheral blood eosinophilia is mainly seen during larval migration through the lung and total serum IgE may be raised. The eosinophil counts are usually elevated in pleural and bronchoalveolar lavage fluids. The identification of the characteristic opeculated eggs in faeces, sputum or bronchoalveolar lavage fluid confirms the diagnosis. Specific serological testing is not performed in the UK but samples may be referred to overseas laboratories for specific IgG and IgM antibody testing when paragonimiasis is suspected.

**Management**

Medical treatment is usually with praziquantel. Some patients may require surgery for persistent pneumothorax, pleural effusion or empyema.

**Amoebiasis**

**Distribution and life cycle**

Amoebiasis is caused by *Entamoeba histolytica*, a protozoan found worldwide. *E. histolytica* is the causative agent of invasive amoebiasis but is morphologically indistinguishable from a related but non-pathogenic species, *E. dispar*. *E. histolytica* is endemic in regions with poor sanitation and poor socioeconomic conditions. The motile trophozoite forms of the parasite live in the lumen of the large intestine where they multiply and differentiate into the cyst forms. Cysts are passed in the faeces and are highly resistant to environmental conditions, facilitating faecal-oral transmission. Ingested cysts are transformed into trophozoites.

**Presentation**

In most infections the organism does not invade the gut mucosa. In a subset of cases the *E. histolytica* trophozoites bind to intestinal epithelial cells via a lectin expressed on the parasite surface. This leads to lysis of the epithelial cells and invasive amoebiasis resulting in colitis. Blood-borne spread of the parasite may lead to the formation of an amoebic liver abscess which may present several months after the initial infection when diarrhoea may be absent.

Amoebic liver abscess may cause irritation of the diaphragm and the patient may present with cough. A serous pleural effusion may occur in conjunction with an amoebic liver abscess and does not indicate extension of the disease. Amoebic liver abscess may also present with chest pain due to hepatic enlargement and inflammation. Elevation of the hemidiaphragm can cause segmental atelectasis of the lung and lead to secondary bacterial pneumonia.

Amoebic pleuropulmonary disease is the most common complication of amoebic liver abscess, occurring in 15% of patients with amoebic liver disease and in 1% of patients with amoebic dysentery. It most commonly occurs by direct extension from a superior right lobe hepatic abscess through the diaphragm into the right lower lobe of the lung, presenting with cough, pleuritic pain and dyspnoea. Pleuropulmonary amoebiasis may also occur following haematogenous spread of organisms to the lungs or lymphatic spread from the liver to the diaphragm. Intrathoracic complications include rupture of an amoebic liver abscess into the pleural cavity with empyema formation which carries a mortality of 15–35%. Infiltration of the lung parenchyma may result in pneumonia or lung abscess formation. Furthermore, a hepatobronchial fistula leading to expectoration of ‘anchovy sauce-like’ purulent sputum can develop. Rarely, a bronchobiliary fistula may occur causing bile expectoration.

**Radiographic features**

Common radiological features include right pleural effusion and basal lung disease. Right lower lobe consolidation may develop, which may progress to abscess formation (figure 3).

**Laboratory investigations**

Eosinophilia is not a feature of amoebic infections. If symptoms of dysentery are present, freshly passed stools should be examined for amoebic trophozoites. Trophozoites are seldom found in sputum, pleural fluid or abscess aspirates. Antibodies directed against the parasite may be detected by a variety of methods. Antibody tests start to become positive after approximately 1 week and have a sensitivity of 99% for the diagnosis of amoebic liver abscess but are only positive in approximately 75% of cases of intestinal infection. The *E histolytica* adhesin may be detected in faecal specimens by ELISA. This test is also helpful in differentiating between *E histolytica* and *E dispar* in asymptomatic patients who pass amoebic cysts.

**Management**

Medical treatment consists of a course of tinidazole or metronidazole to kill trophozoites in tissue, followed by diloxanide furoate or paromomycin to eliminate cysts from the intestinal lumen. Surgical treatment of pulmonary amoebiasis may be required when there is direct pulmonary involvement or spread to pleura.

**CONDITIONS PRESENTING WITH DIFFUSE LUNG DISEASE**

**Transitory pulmonary infiltrates**

**Ascariasis**

**Distribution and life cycle**

Ascariasis is caused by *Ascaris lumbricoides*, the round worm. It is common worldwide in areas with poor sanitation where there is faecal contamination of soil or food. Transmission of the disease is faecal-oral. After eggs are ingested they hatch and larvae migrate via the portal circulation to the liver then via the heart to reach the lungs 2 weeks after ingestion. Larvae then ascend to the trachea, are swallowed and eventually develop into adults in the small intestine, producing eggs 10–12 weeks after ingestion.

![Image](http://thorax.bmj.com/)
**Presentation**
During the second week of infection, as the larvae invade the lung tissue, a small proportion of patients become symptomatic. Loeffler’s syndrome is caused by larval migration into the alveoli which triggers an allergic response leading to respiratory symptoms including cough, wheeze, dyspnoea, chest pain, fever and haemoptysis. The illness usually resolves spontaneously after several weeks.

**Imaging features**
During pulmonary migration, transient nodular or diffuse pulmonary infiltrates on the chest x-ray support the diagnosis of Loeffler’s syndrome. Chronic eosinophilic pneumonia has been associated with ascariasis of the lung.\(^{30}\) Spontaneous pneumothoraces have been described infrequently.\(^{21}\)

**Laboratory diagnosis**
During larval migration a leucocytosis and peripheral blood eosinophilia are often present and total serum IgE may be elevated. Eosinophilis and larvae may be found in sputum. The diagnosis is confirmed by finding characteristic *Ascaris* eggs in the stool on microscopy, although these may not be passed until after resolution of the pulmonary symptoms. Serological tests are not routinely available.

**Management**
A single dose of albendazole is the treatment of choice. Mebendazole and pyrantel pamoate are alternatives.\(^{28}\)

**Hookworm infections**

**Distribution and life cycle**
Ancylostomiasis is common in tropical and subtropical countries, caused by two species of hookworm (*Ancylostoma duodenale* and *Necator americanus*). *A duodenale* is also found in the Middle East and southern Europe; *N americanus* is found sporadically in the southeastern USA. Hookworm eggs are passed in faeces and develop in soil into filariform larvae able to penetrate the skin of the human host. Poor sanitation and the absence of footwear favour transmission. The larvae penetrate blood vessels and undergo heart–lung migration before breaking out into the alveoli and ascending to the pharynx from where they are swallowed. The hookworms subsequently mature into adults in the small intestine. Eggs first appear in the stool 5 weeks after skin invasion.

**Presentation**
Pulmonary manifestations are usually mild. During larval migration in the lung the hookworm may cause symptoms and signs consistent with Loeffler’s syndrome including dry cough, wheeze, dyspnoea and fever.

**Imaging features**
The radiographic changes are consistent with Loeffler’s syndrome and an eosinophilic pneumonia with transient non-segmental areas of consolidation.\(^{13}\)

**Laboratory diagnosis**
Peripheral blood eosinophilia is found during larval migration and commonly persists during gastrointestinal infection. Although their appearance may be delayed, finding eggs in the stool supports the diagnosis. Serological tests are not useful in view of many cross-reactions with other helminthic infections.\(^{27}\)

**Management**
Recommended treatment consists of a single dose of albendazole. Mebendazole and pyrantel pamoate are alternatives.\(^{28}\)

**Toxocariasis**

**Distribution and life cycle**
Human toxocariasis is usually caused by the dog round worm *Toxocara canis* which commonly infects juvenile dogs and has a worldwide distribution. Humans, who are incidental hosts, are usually infected by the ingestion of eggs. The disease primarily affects children, who acquire the infection through contact with soil contaminated with embryonated eggs. Fresh animal faeces are not infectious as the eggs require 2–3 weeks to embryonate in the soil. Ingested eggs hatch in the stomach. Larvae penetrate the mucosa of the gut and enter the mesenteric vessels from where they migrate to the lungs and other organs.

**Presentation**
Most infections occur in children and most are asymptomatic. Patients may present with immunologically-mediated symptoms including cough, dyspnoea and wheeze which may present as asthma or bronchitis. Presenting signs may include hepatomegaly, splenomegaly and ocular lesions.

**Radiographic features**
Radiological features may include transient localised changes or widespread patchy areas of consolidation.\(^{13}\)

**Laboratory diagnosis**
*Toxocara* larvae do not develop into adults in the human host, so eggs are not passed in human faeces. Visceral larva migrans is characterised by persistent peripheral eosinophilia and leucocytosis. A high degree of eosinophilia in the differential cell count of bronchoalveolar lavage fluid may support the diagnosis.\(^{72}\) Serological tests are available at reference laboratories. Although positive *Toxocara* serology supports a diagnosis of visceral larva migrans, titres may remain elevated for years and other causes of illness should be considered.\(^{54}\) Children suspected of ingesting infective *Toxocara* eggs may be investigated with full blood count and *Toxocara* serology tests at baseline and at 3 months. In practice this is seldom required as, in many cases where dog faeces have been ingested, it is possible to establish that the sample is relatively fresh and thus not likely to contain embryonated eggs. Tissue biopsy is not required for the diagnosis of visceral larva migrans.

**Management**
Ocular disease is treated under the supervision of an ophthalmologist with local or systemic steroids. Anthelmintics are not usually given. Visceral larva migrans is treated with albendazole. Corticosteroids may be required in more severe cases.\(^{28}\)

**Alveolar/interstitial changes**

**Schistosomiasis**

**Distribution and life cycle**
Schistosomiasis is endemic throughout the tropics and it is estimated that more than 200 million people worldwide are infected.\(^{55}\) There are three main species of schistosomes: *Schistosoma mansoni*, *Schistosoma haematobium* and *Schistosoma japonicum*. The adult trematode worms are found in the vesical plexus (*S haematobium*) or in the mesenteric veins (*S mansoni* and *S japonicum*). Their eggs are excreted in urine or faeces respectively. Humans are infected by cercariae during contact with fresh water. The organisms enter the circulation and pass through the heart, lungs and then the liver to reach the target venous plexus. There the worms mature and mate, releasing eggs 4–6 weeks after skin penetration. The initial release of eggs may give rise to acute schistosomiasis which occurs predominantly in non-immune hosts. Eggs that are not passed into the
bladder or intestinal lumen are the main cause of chronic disease, causing granulomatous reactions and fibrosis. In severe long-standing *S. mansonii* and *S. japonicum* infections, the development of hepatosplenomegaly and portal hypertension may lead to diversion of eggs to the lung vasculature. This results in obliterative arteritis which may cause pulmonary hypertension.

**Presentation**

In non-endemic countries, returned non-immune travellers may present with acute schistosomiasis while migrants from endemic countries may present with chronic disease. Acute schistosomiasis (Katayama fever) may present with fever, cough, dyspnoea, rash and arthralgias. The precise pathogenesis of Katayama fever is unknown, but it is thought to be due to an immune complex phenomenon initiated by eggs laid by maturing schistosomes. Typically, symptoms occur 4–6 weeks after infection. In acute schistosomiasis, serological tests are often negative and eggs are not detectable, requiring the diagnosis to be made on clinical and epidemiological grounds. In heavy infections, the migratory phase through the lungs may produce a pneumonitis resembling that produced during hookworm migration. A Loeffler-like syndrome may occur during the treatment of heavy infections. Acute symptoms are usually self-limiting. In the chronic stage the commonest symptoms are dyspnoea, reduced exercise tolerance and chest pain. Clinical signs of severe hypoxaemia such as digital clubbing may be seen. Since schistosomiasis is an important cause of pulmonary hypertension, it should always be considered as a differential diagnosis in patients from endemic countries. The chronic form of schistosomiasis may also cause pulmonary arteriovenous fistulas.

**Radiological features**

Nodular ill-defined lesions or reticulonodular changes may be seen on the chest x-ray in acute pulmonary schistosomiasis (figure 4). Although radiological findings are usually transitory in acute infection, chest x-rays may show features resembling granulomatous disease or tuberculosis. In chronic lung disease, interstitial or granulomatous changes are caused by the widespread deposition of eggs in the pulmonary vasculature. A CT scan of the thorax may show nodular changes and ground glass opacification (figure 5).

**Laboratory investigation**

Peripheral blood eosinophilia is present in more than 65% of patients. Eggs of the *Schistosoma* species may be found in faeces, urine and sputum or bronchoalveolar lavage 6 weeks after infection. Eggs of *S. haematobium* are most likely to be found in late morning urine samples. Terminal urine specimens maximise sensitivity. IgG antibodies to *Schistosoma* egg antigen are detectable 6–12 weeks following infection and can be measured by ELISA. Such assays have sensitivities of >90% for the diagnosis of schistosomiasis. These tests may remain positive for several years and are not helpful for monitoring response to treatment. Serological testing in asymptomatic travellers should be delayed for a period of 3 months following exposure to fresh water to allow time for seroconversion. Schistosomal serology may be negative, especially in Katayama fever, but if positive it provides helpful diagnostic information.

**Management**

The treatment of choice for schistosomiasis is praziquantel. In acute schistosomiasis (Katayama fever) praziquantel is administered under steroid cover. A second course of praziquantel may need to be given 3–6 months later to eradicate any schistosomes that may have survived the first course of treatment. Treatment is less beneficial in advanced chronic disease.

**Strongyloides**

**Distribution and life cycle**

Strongyloides is caused by the nematode *Strongyloides stercoralis* and is prevalent in tropical and subtropical countries. Filariform larvae penetrate the skin, enter blood vessels and undergo heart and lung migration. They migrate into alveoli and subsequently ascend to the trachea. Larvae are swallowed and develop in the small intestine into adult worms which produce eggs. These are deposited in the intestinal mucosa where they hatch into rhabditiform larvae which are excreted in faeces. Occasionally, rhabditiform larvae mature to the filariform stage while still in the bowel lumen. These filariform larvae may penetrate the bowel wall or the perianal skin to initiate a new cycle (autoinfection). Thus, in the absence of treatment, an individual may harbour *Strongyloides* for several decades.

**Presentation**

Clinically the infection is often asymptomatic, but mild symptoms may occur in the initial stages of lung migration. In the immunocompromised patient (including those on steroid...
<table>
<thead>
<tr>
<th>Condition</th>
<th>Presentation</th>
<th>Imaging features</th>
<th>Geographical distribution</th>
<th>Incubation period</th>
<th>Investigations</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cystic lesions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydatidosis</td>
<td>Symptoms due to mass effect Chest pain, cough, haemoptysis Hypersensitivity reaction Secondary abscess formation</td>
<td>Single or multiple lung cysts Pleural effusion Pneumothorax Hydro-pneumothorax</td>
<td>Wide distribution: Mediterranean borders, East and Central Asia, sub-Saharan Africa, Russia, China, South America</td>
<td>Months to decades after exposure</td>
<td>Hydatid serology positive in 50-60% Blood eosinophilia uncommon unless cyst leaking</td>
<td>Aspiration and microscopy Surgery Albendazole with or without praziquantel Aspiration</td>
</tr>
<tr>
<td>Coin lesions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dirofilariasis</td>
<td>Chest pain, cough, haemoptysis, wheezing Fever, malaise</td>
<td>Coin lesion with or without calcification</td>
<td>Pulmonary dirofilariasis reported from USA, Japan, Australia, South America</td>
<td>May be years after exposure</td>
<td>Blood eosinophilia uncommon Biopsy usually diagnostic</td>
<td>Surgical excision</td>
</tr>
<tr>
<td>Consolidation/pleural effusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paragonimiasis</td>
<td>Reumatic chest pain, cough, fever, haemoptysis</td>
<td>Pulmonary infiltrates Consolidation or cystic lesions Pleural effusion Pneumothorax</td>
<td>Asia, West Africa, Central and South America</td>
<td>1–27 months</td>
<td>Eggs in sputum Eosinophilia in peripheral blood, pleural fluid or bronchoalveolar lavage Serology</td>
<td>Praziquantel</td>
</tr>
<tr>
<td>Amoebiasis</td>
<td>Right upper quadrant or shoulder tip pain Cough and bile expectoration</td>
<td>Pleural effusion, atelectasis, Emphyema Amoebic lung abscess Secondary pneumonia Hepatobronchial fistula</td>
<td>Widely distributed</td>
<td>Weeks to years after exposure</td>
<td>Serology (may be negative, especially in early disease) Does not cause eosinophilia; usually does cause neutrophilia</td>
<td>Theridazole (or mebendazole) followed by diloxanide furorate or paromomycin</td>
</tr>
<tr>
<td>Diffuse disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transient pulmonary infiltrates</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascariasis</td>
<td>Cough, wheeze, dyspnoea, chest pain, fever Loefller's syndrome Haemoptysis</td>
<td>Transient pulmonary infiltrates Bacterial pneumonia, eosinophilic pneumonia Pneumothorax</td>
<td>Worldwide in areas where sanitation is poor (faecal-oral transmission)</td>
<td>1–2 weeks from infection to onset of pulmonary symptoms</td>
<td>Larvae in pulmonary, gastric secretions Eggs in sputum in established infection with adult worms, may be absent in larval migratory phase Blood eosinophilia during larval migration</td>
<td>Albendazole, mebendazole, piperacine, or pyrantel pamoate</td>
</tr>
<tr>
<td>Hookworm infection</td>
<td>Cough, wheeze, dyspnoea, chest pain, fever Loefller's syndrome</td>
<td>Transient pulmonary infiltrates Eosinophilic pneumonia</td>
<td>Widely distributed; infection usually by contact of bare feet with faecally contaminated soil</td>
<td>Pulmonary manifestations start within 10 days of infection, can continue for more than one month</td>
<td>Blood eosinophilia during migration, which may persist Eggs in sputum in established infection with adult worms Eggs may be absent in larval migratory phase</td>
<td>Albendazole, mebendazole or pyrantel pamoate</td>
</tr>
<tr>
<td>Toxocariasis</td>
<td>Cough, dyspnoea, wheeze, asthma or bronchitis Hepatomegaly, splenomegaly, ocular lesions</td>
<td>Pulmonary infiltrates Secondary bacterial pneumonia</td>
<td>Worldwide distribution (adult worms live in gut of cats and dogs)</td>
<td>Several weeks</td>
<td>Peripheral blood eosinophilia common Eosinophilia in bronchoalveolar lavage</td>
<td>Albendazole for visceral disease</td>
</tr>
</tbody>
</table>

Alveolar’s interstitial changes

Continued


Review group.bmj.com on April 7, 2017 - Published by group.bmj.com
therapy), a hyperinfection syndrome can result in severe disseminated infection which may cause Gram-negative sepsis and death. Respiratory symptoms may be non-specific and, apart from gastrointestinal complaints, symptoms of asthma might be the only feature. In patients with new onset bronchial asthma or worsening of asthmatic complaints, symptoms of asthma should be considered especially in patients from endemic countries. In immunosuppressed patients with hyperinfection, symptoms and signs consistent with adult respiratory distress syndrome may be seen. In disseminated disease, extensive intra-alveolar haemorrhage has been reported and should be considered as a cause of acute deterioration.

Radiological findings

In *Strongyloides* hyperinfection, pulmonary infiltrates are the most frequent feature seen on chest radiography. Radiographic changes may include miliary nodules, reticular opacities and airspace opacities ranging from multifocal to lobar distribution. These are thought to be due to secondary infection, haemorrhage, inflammatory pneumonitis and bacterial abscess formation. If widespread air space shadowing is seen on chest radiography, adult respiratory distress syndrome should be strongly suspected. Rare manifestations of pulmonary strongyloidiasis include granulomatous changes leading to pulmonary fibrosis.

Laboratory investigations

Blood eosinophilia is seen in more than 75% of patients with chronic infection but may be absent in the hyperinfection syndrome in immunocompromised patients. A definitive diagnosis is made by demonstration of rhabditiform larvae in stool, sputum or duodenal aspirates. Filariform larvae may also be seen. Larvae may be identified on direct microscopy but specialised culture techniques are more likely to yield positive results. Antibody assays have sensitivities of approximately 90%; however, cross-reactions occur with other helminth infections and antibody levels may be low in immunocompromised patients.

Management

Treatment with ivermectin is usually effective. In cases of hyperinfection, repeated treatments are required and expert parasitological advice should be sought.

Tropical pulmonary eosinophilia

Presentation

Tropical pulmonary eosinophilia (TPE) typically results from a hypersensitivity reaction to the lymphatic filarial parasites *Wuchereria bancrofti* and *Brugia malayi* found in endemic regions of south east Asia, India, China and Africa. The most common clinical manifestation of filariasis is elephantiasis resulting from lymphatic obstruction of lymphatic vessels. The syndrome of TPE is thought to be an immunological response to microfilariae rather than acute infection. Clinically, TPE typically has slow onset over several months, with respiratory symptoms including cough, dyspnoea and wheeze which may be more severe at night. Systemic features including fever, malaise and weight loss may also occur. By contrast, Loeffler’s syndrome is caused by larval migration of nematodes such as *Strongyloides*, *Ascariis* or hookworm which results in wheeze, cough and dyspnoea of acute onset and rarely lasts more than a few weeks.

Radiological findings

Bilateral fine nodular or reticulonodular shadowing have been described on plain chest radiography. However, it has been suggested that a CT scan of the thorax might be more sensitive...
to detect reticulonodular pulmonary opacities and mediastinal lymphadenopathy.60

**Laboratory investigations**

High titres of antifilarial antibodies and peripheral blood eosinophilia are present. The extensive immune response leads to rapid clearance of microfilariae from the blood and, in order to diagnose TPE, it is essential that no microfilariae can be found in the peripheral blood. Total serum IgE is raised, as are the peripheral blood. Total serum IgE is raised, as are specific antifilarial IgE and IgG antibody levels. Bronchoalveolar lavage may show evidence of an eosinophilic alveolitis with a high concentration of eosinophils.61 Specific antifilarial IgE and IgG antibodies have also been detected in bronchoalveolar lavage samples.62

**Management**

Pulmonary abnormalities usually progressively worsen without treatment. Concomitant infection with other filarial species must be investigated prior to treatment. Treatment usually involves diethylcarbamazine under expert guidance; however, it is sometimes given in combination with albendazole to improve efficacy.63 64 Even after treatment, pulmonary symptoms may progress and interstitial lung disease might develop leading to chronic respiratory failure.65

**Non-infectious causes of pulmonary eosinophilia**

Other causes of pulmonary eosinophilia need to be considered in the differential diagnosis of parasitic lung infections. Idiopathic lung diseases such as acute eosinophilic pneumonia, chronic eosinophilic pneumonia and idiopathic hypereosinophilic syndrome and lung diseases of known cause such as allergic bronchopulmonary aspergillosis, bronchocentric granulomatosis, drug reactions and eosinophilic vasculitis (Churg–Strauss syndrome) can cause pulmonary and peripheral blood eosinophilia.66 67

**CONCLUSIONS**

This review outlines the symptoms, signs, investigation and treatment of parasitic lung diseases which are summarised in table 1. The clinical presentation and radiology of many of these diseases may share common features with tuberculosis and malignancy. When symptoms of lung disease are associated with gastrointestinal, hepatobiliary or cutaneous symptoms or a peripheral eosinophilia, there should be a high index of suspicion for parasitic disease. With increasing travel and migration, it is important to consider parasitic infections in the differential diagnosis of lung diseases. Parasitic lung infections have been described in patients following chemotherapy or transplantation and need to be considered in the differential diagnosis of lung infections in immunocompromised individuals.68 69 Direct identification of the causative organisms may be achieved definitively through microscopic examination of stool or respiratory tract samples, or indirectly via serological testing. If identified early, most parasitic lung diseases are curable with medical treatment. Further information on the distribution of parasitic lung diseases and treatment may be obtained from the World Health Organization.26 70

**Funding** PLC and AG are supported by the UCL Hospitals Comprehensive Biomedical Research Centre Infection Theme. AG was supported by a Public Health Career Scientist award from the UK Department of Health.

**Competing interests** None.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**


8 of 9


Downloaded from http://thorax.bmj.com/ on April 7, 2017 - Published by group.bmj.com


Parasitic infections of the lung: a guide for the respiratory physician

H Kunst, D Mack, O M Kon, A K Banerjee, P Chiodini and A Grant

Thorax published online September 29, 2010

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2010/09/29/thx.2009.132217

These include:

This article cites 64 articles, 15 of which you can access for free at:
http://thorax.bmj.com/content/early/2010/09/29/thx.2009.132217#BIBL

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/